Intrathoracic muscle flap transposition in the treatment of fibrocavernous tuberculosis

Yau-Lin Tseng, Ming Ho Wu, Mu Yen Lin, Wu-Wei Lai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background and objective: Conventionally, pulmonary resection with thoracoplasty is used to treat fibrocavernous complication of pulmonary tuberculosis. This operation is usually bloody, time-consuming with complicated postoperative course. To prevent massive blood loss and preserved pulmonary function, a more simplified operative procedure, cavernostomy combined intrathoracic muscle flap transposition was used and the outcome was evaluated in this study. Design: Retrospective review. Methodology: Between December 1989 and June 1996, a total of ten patients with fibrocavernous pulmonary tuberculosis were managed using cavernostomy combined with intrathoracic muscle flap transposition. Five of them had concomitant aspergilloma within the cavity while three had multiple drug resistant pulmonary tuberculosis. The muscle flap was used to plombage the cavity and reinforce the closure of bronchopleural fistula after cavernostomy. Results: Six postoperative complications occurred in five patients, including reformation of cavity (2), bronchopleurocutaneous fistulae (3), and postoperative bleeding (1). The success or failure of intrathoracic muscle flap transposition on patients with fibrocavernous tuberculosis was significantly correlated with the size of the cavity (194.0 ± 11.2 vs. 283.0 ± 44.6 cm3, P=0.016) and the number of bronchopleural fistulae (1.6 ± 0.4 vs. 4.0 ± 0.4, P = 0.008). There was no operative death and in long term follow-up, there was no recurrence of hemoptysis or deterioration of pulmonary function in the successful group of patients. Conclusions: Cavernostomy combined with intrathoracic muscle flap transposition can be used to treat well-selected fibrocavernous pulmonary tuberculosis patients, except on patients with large size cavity, multiple bronchopleural fistulae or multiple drug resistance tuberculosis. (C) 2000 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)666-670
Number of pages5
JournalEuropean Journal of Cardio-thoracic Surgery
Volume18
Issue number6
DOIs
Publication statusPublished - 2000 Dec 16

Fingerprint

Tuberculosis
Pulmonary Tuberculosis
Muscles
Fistula
Lung
Therapeutics
Thoracoplasty
Multidrug-Resistant Tuberculosis
Hemoptysis
Operative Surgical Procedures
Multiple Drug Resistance
Hemorrhage
Recurrence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{fc544ce944ba4c4088398a669e6d2fdc,
title = "Intrathoracic muscle flap transposition in the treatment of fibrocavernous tuberculosis",
abstract = "Background and objective: Conventionally, pulmonary resection with thoracoplasty is used to treat fibrocavernous complication of pulmonary tuberculosis. This operation is usually bloody, time-consuming with complicated postoperative course. To prevent massive blood loss and preserved pulmonary function, a more simplified operative procedure, cavernostomy combined intrathoracic muscle flap transposition was used and the outcome was evaluated in this study. Design: Retrospective review. Methodology: Between December 1989 and June 1996, a total of ten patients with fibrocavernous pulmonary tuberculosis were managed using cavernostomy combined with intrathoracic muscle flap transposition. Five of them had concomitant aspergilloma within the cavity while three had multiple drug resistant pulmonary tuberculosis. The muscle flap was used to plombage the cavity and reinforce the closure of bronchopleural fistula after cavernostomy. Results: Six postoperative complications occurred in five patients, including reformation of cavity (2), bronchopleurocutaneous fistulae (3), and postoperative bleeding (1). The success or failure of intrathoracic muscle flap transposition on patients with fibrocavernous tuberculosis was significantly correlated with the size of the cavity (194.0 ± 11.2 vs. 283.0 ± 44.6 cm3, P=0.016) and the number of bronchopleural fistulae (1.6 ± 0.4 vs. 4.0 ± 0.4, P = 0.008). There was no operative death and in long term follow-up, there was no recurrence of hemoptysis or deterioration of pulmonary function in the successful group of patients. Conclusions: Cavernostomy combined with intrathoracic muscle flap transposition can be used to treat well-selected fibrocavernous pulmonary tuberculosis patients, except on patients with large size cavity, multiple bronchopleural fistulae or multiple drug resistance tuberculosis. (C) 2000 Elsevier Science B.V.",
author = "Yau-Lin Tseng and Wu, {Ming Ho} and Lin, {Mu Yen} and Wu-Wei Lai",
year = "2000",
month = "12",
day = "16",
doi = "10.1016/S1010-7940(00)00594-7",
language = "English",
volume = "18",
pages = "666--670",
journal = "European Journal of Cardio-thoracic Surgery",
issn = "1010-7940",
publisher = "Elsevier",
number = "6",

}

Intrathoracic muscle flap transposition in the treatment of fibrocavernous tuberculosis. / Tseng, Yau-Lin; Wu, Ming Ho; Lin, Mu Yen; Lai, Wu-Wei.

In: European Journal of Cardio-thoracic Surgery, Vol. 18, No. 6, 16.12.2000, p. 666-670.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intrathoracic muscle flap transposition in the treatment of fibrocavernous tuberculosis

AU - Tseng, Yau-Lin

AU - Wu, Ming Ho

AU - Lin, Mu Yen

AU - Lai, Wu-Wei

PY - 2000/12/16

Y1 - 2000/12/16

N2 - Background and objective: Conventionally, pulmonary resection with thoracoplasty is used to treat fibrocavernous complication of pulmonary tuberculosis. This operation is usually bloody, time-consuming with complicated postoperative course. To prevent massive blood loss and preserved pulmonary function, a more simplified operative procedure, cavernostomy combined intrathoracic muscle flap transposition was used and the outcome was evaluated in this study. Design: Retrospective review. Methodology: Between December 1989 and June 1996, a total of ten patients with fibrocavernous pulmonary tuberculosis were managed using cavernostomy combined with intrathoracic muscle flap transposition. Five of them had concomitant aspergilloma within the cavity while three had multiple drug resistant pulmonary tuberculosis. The muscle flap was used to plombage the cavity and reinforce the closure of bronchopleural fistula after cavernostomy. Results: Six postoperative complications occurred in five patients, including reformation of cavity (2), bronchopleurocutaneous fistulae (3), and postoperative bleeding (1). The success or failure of intrathoracic muscle flap transposition on patients with fibrocavernous tuberculosis was significantly correlated with the size of the cavity (194.0 ± 11.2 vs. 283.0 ± 44.6 cm3, P=0.016) and the number of bronchopleural fistulae (1.6 ± 0.4 vs. 4.0 ± 0.4, P = 0.008). There was no operative death and in long term follow-up, there was no recurrence of hemoptysis or deterioration of pulmonary function in the successful group of patients. Conclusions: Cavernostomy combined with intrathoracic muscle flap transposition can be used to treat well-selected fibrocavernous pulmonary tuberculosis patients, except on patients with large size cavity, multiple bronchopleural fistulae or multiple drug resistance tuberculosis. (C) 2000 Elsevier Science B.V.

AB - Background and objective: Conventionally, pulmonary resection with thoracoplasty is used to treat fibrocavernous complication of pulmonary tuberculosis. This operation is usually bloody, time-consuming with complicated postoperative course. To prevent massive blood loss and preserved pulmonary function, a more simplified operative procedure, cavernostomy combined intrathoracic muscle flap transposition was used and the outcome was evaluated in this study. Design: Retrospective review. Methodology: Between December 1989 and June 1996, a total of ten patients with fibrocavernous pulmonary tuberculosis were managed using cavernostomy combined with intrathoracic muscle flap transposition. Five of them had concomitant aspergilloma within the cavity while three had multiple drug resistant pulmonary tuberculosis. The muscle flap was used to plombage the cavity and reinforce the closure of bronchopleural fistula after cavernostomy. Results: Six postoperative complications occurred in five patients, including reformation of cavity (2), bronchopleurocutaneous fistulae (3), and postoperative bleeding (1). The success or failure of intrathoracic muscle flap transposition on patients with fibrocavernous tuberculosis was significantly correlated with the size of the cavity (194.0 ± 11.2 vs. 283.0 ± 44.6 cm3, P=0.016) and the number of bronchopleural fistulae (1.6 ± 0.4 vs. 4.0 ± 0.4, P = 0.008). There was no operative death and in long term follow-up, there was no recurrence of hemoptysis or deterioration of pulmonary function in the successful group of patients. Conclusions: Cavernostomy combined with intrathoracic muscle flap transposition can be used to treat well-selected fibrocavernous pulmonary tuberculosis patients, except on patients with large size cavity, multiple bronchopleural fistulae or multiple drug resistance tuberculosis. (C) 2000 Elsevier Science B.V.

UR - http://www.scopus.com/inward/record.url?scp=0033673158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033673158&partnerID=8YFLogxK

U2 - 10.1016/S1010-7940(00)00594-7

DO - 10.1016/S1010-7940(00)00594-7

M3 - Article

C2 - 11113673

AN - SCOPUS:0033673158

VL - 18

SP - 666

EP - 670

JO - European Journal of Cardio-thoracic Surgery

JF - European Journal of Cardio-thoracic Surgery

SN - 1010-7940

IS - 6

ER -